Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors

AbstractProinflammatory cytokines have been approved by the Food and Drug Administration for the treatment of metastatic melanoma and renal carcinoma. However, effective cytokine therapy requires high-dose infusions that can result in antidrug antibodies and/or systemic side effects that limit long-term benefits. To overcome these limitations, we developed a clinically translatable cytokine delivery platform composed of… Continue reading Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors